滴基-4调节慢性心力衰竭的左心室功能障碍,通过血管生成依赖和独立的作用
Toshimasa Shigeta1, Morihiko Aoyama, Yasuko K Bando
1Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Circulation
|October 5, 2012
概括
双基酸酶-4 (DPP4) 抑制通过改善血管功能和心脏收缩性来逆转腹痛性心力衰竭 (DHF). 循环中的DPP4水平可以作为监测DHF的生物标志物.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 双基化酶-4 (DPP4) 抑制对急性心肌缺血有好处.
- 在没有冠状动脉疾病的情况下,DPP4在慢性心力衰竭 (CHF) 中的作用尚不清楚.
研究的目的:
- 调查DPP4在扩张性左心室功能障碍 (DHF) 中的作用.
- 探索DPP4抑制作为DHF的治疗策略.
主要方法:
- 在老鼠和人类心脏毛细血管中定位的膜结合DPP4.
- 研究了糖尿病老鼠和压力过重的老鼠的DPP4激活.
- 在患有 DHF 的患者中评估循环 DPP4 活性.
主要成果:
- 糖尿病激活DPP4,减少血管生成,并通过MMP-2/TIMP-2比率引起纤维化DHF.
- 抑制DPP4可以逆转糖尿病DHF和微血管病变.
- DPP4抑制通过GLP-1/cAMP通路逆转压力过载诱导的DHF.
- 在DHF患者中循环DPP4活动与冠状动脉鼻活动和心声学参数相关.
结论:
- DPP4抑制通过局部和全身机制逆转DHF.
- 抑制DPP4会影响血管生成和心脏收缩性.
- 循环中的DPP4可能是监测DHF的潜在生物标志物.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

